GI cancer update from ASCO 2025

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
GI CONNECT member Dr Lizzy Smyth joined us at ASCO 2025 to share her insights on new gastric cancer data from the MATTERHORN and DESTINY-Gastric04 studies presented at the congress.

How will this data impact clinical practice? Watch Dr Smyth’s update to find out.

Studies mentioned in this video:

- MATTERHORN: Event-free survival in MATTERHORN: A randomised, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy in resectable gastric/gastroesophageal junction cancer. Janjigian Y, et al. Abstract LBA5, ASCO 2025

- DESTINY-Gastric04: Trastuzumab deruxtecan vs ramucirumab + paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer or gastroesophageal junction adenocarcinoma: Primary analysis of the randomised, Phase 3 DESTINY-Gastric04 study. Shitara K, et al. Abstract LBA4002, ASCO 2025

Get more updates from ASCO 2025 in GU oncology, breast cancer, obstetrics and gynecology and lung cancer on our website: https://cor2ed.com/n-connect/programmes/highlights-asco-2025/


Follow GI CONNECT on social media:

X - https://x.com/giconnectInfo

LinkedIn - https://www.linkedin.com/company/giconnect



Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.



This video was developed by https://cor2ed.com/

Published June 2025
Category
Oncology
Be the first to comment

Up Next